Dr Marta Boffito, MD, PhD, FRCP, is a Consultant physician at Chelsea and Westminster Hospital, and Reader at Imperial College, London, London UK.
She is the Clinical Research Lead of the Clinical Research Facility and HIV Service Lead at Chelsea and Westminster Hospital, where she runs numerous research projects and clinical trials, she consults on complex pharmacological issues, sees patients with HIV (she founded the first HIV over-50-years clinic in London, UK), and teaches HIV medicine and pharmacology at Imperial College London and in various National and International settings.
She trained in Italy, the USA, and the UK and has a special interest in antiretroviral drug pharmacology: from prevention to treatment. In these areas she contributes to the educational, scientific, and guideline-formulation activities of national bodies including the British HIV Association.
She is a WHO advisor and has been involved in capacity building programmes for resource-limited settings (e.g. Uganda) and is an applicant on numerous successful collaborative grants.
Funding: Gates Foundation, UNITAID, USAID, ViiV, Gilead, MSD, BHIVA.
et al., 2021, Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV & Aging Workshop., Aids Res Hum Retroviruses
et al., 2018, CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study (vol 24, pg 98, 2018), Journal of Neurovirology, Vol:24, ISSN:1355-0284, Pages:388-389
et al., 2013, Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies., J Acquir Immune Defic Syndr, Vol:62, Pages:60-66
et al., 2012, British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012, Hiv Medicine, Vol:13, ISSN:1464-2662, Pages:1-85
et al., 2012, Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults., J Acquir Immune Defic Syndr, Vol:60, Pages:295-298